These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 1340374)

  • 1. [Optimization of the use of cyclosporin in renal transplantation].
    Tedesco Júnior HS; Pereira AB; Luconi PS; Vaz ML; Ajzen H; Medina JO
    Rev Assoc Med Bras (1992); 1992; 38(4):183-94. PubMed ID: 1340374
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of tacrolimus compared with cyclosporin A microemulsion in renal transplantation: 2 year follow-up results.
    Krämer BK; Montagnino G; Del Castillo D; Margreiter R; Sperschneider H; Olbricht CJ; Krüger B; Ortuño J; Köhler H; Kunzendorf U; Stummvoll HK; Tabernero JM; Mühlbacher F; Rivero M; Arias M;
    Nephrol Dial Transplant; 2005 May; 20(5):968-73. PubMed ID: 15741208
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Measurement of cyclosporine A in rat tissues and human kidney transplant biopsies--a method suitable for small (<1 mg) samples.
    Noll BD; Coller JK; Somogyi AA; Morris RG; Russ GR; Hesselink DA; van Gelder T; Sallustio BC
    Ther Drug Monit; 2011 Dec; 33(6):688-93. PubMed ID: 22105584
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cyclosporine trough concentrations in predicting allograft rejection and renal toxicity up to 12 months after renal transplantation.
    Min DI; Perry PJ; Chen HY; Hunsicker LG
    Pharmacotherapy; 1998; 18(2):282-7. PubMed ID: 9545147
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cyclosporin exposure correlates with 1 year graft function and histological damage in renal transplanted patients.
    di Paolo S; Teutonico A; Stallone G; Infante B; Schena A; Grandaliano G; Battaglia M; Ditonno P; Schena PF
    Nephrol Dial Transplant; 2004 Aug; 19(8):2107-12. PubMed ID: 15187199
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chronic rejection of rat renal allograft. I. Histological differentiation between chronic rejection and cyclosporin nephrotoxicity.
    Yilmaz S; Taskinen E; Paavonen T; Mennander A; Häyry P
    Transpl Int; 1992 May; 5(2):85-95. PubMed ID: 1627245
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The importance of early cyclosporine levels in pediatric kidney transplantation.
    Matas AJ; Gillingham KJ; Chavers BM; Nevins T; Kashtan C; Mauer SM; Payne WD; Gruessner R; Najarian JS
    Clin Transplant; 1996 Dec; 10(6 Pt 1):482-6. PubMed ID: 8996767
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnostic utility of whole blood cyclosporine measurements in renal transplantation using triple therapy.
    Nankivell BJ; Hibbins M; Chapman JR
    Transplantation; 1994 Nov; 58(9):989-96. PubMed ID: 7974738
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cyclosporine nephrotoxicity: associated allograft dysfunction at low trough concentration.
    Jankauskiene A; Druskis V; Laurinavicius A
    Clin Nephrol; 2001 Dec; 56(6):S27-9. PubMed ID: 11770808
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and side-effects of cyclosporine dose monitoring with levels 6 h after the morning dose in heart transplant patients.
    Cantarovich M; Besner JG; Fitchett DH; Latter DA
    Clin Transplant; 1997 Oct; 11(5 Pt 1):399-405. PubMed ID: 9361930
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Do cyclosporin profiles provide useful information in the management of renal transplant recipients?
    Bowles MJ; Waters JB; Lechler RI; Williams G
    Nephrol Dial Transplant; 1996 Aug; 11(8):1597-602. PubMed ID: 8856218
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Nephrotoxicity of cyclosporin A after kidney transplantation].
    Rainiene T; Papinigiene L; Laurinavicius A
    Medicina (Kaunas); 2003; 39 Suppl 1():161-5. PubMed ID: 12761440
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detrimental effects of cyclosporin A on long-term graft survival in familial Mediterranean fever renal allograft recipients: experience of two transplantation centers.
    Shabtai M; Ben-Haim M; Zemer D; Malinger-Saavedra P; Rosin D; Kuriansky J; Lustig S; Shabtai EL; Shapira Z; Ayalon A
    Isr Med Assoc J; 2002 Nov; 4(11 Suppl):935-9. PubMed ID: 12455184
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A prospective study of cyclosporine concentration in relation to its therapeutic effect and toxicity after renal transplantation.
    Lindholm A; Dahlqvist R; Groth GG; Sjöqvist F
    Br J Clin Pharmacol; 1990 Sep; 30(3):443-52. PubMed ID: 2223423
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An open randomized study comparing immunosuppression therapy initiated before or after kidney transplantation in haploidentical living recipients.
    Câmara NO; Dias MF; Pacheco-Silva A
    Clin Transplant; 2004 Aug; 18(4):450-5. PubMed ID: 15233825
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nature and mediators of renal lesions in kidney transplant patients given cyclosporine for more than one year.
    Benigni A; Bruzzi I; Mister M; Azzollini N; Gaspari F; Perico N; Gotti E; Bertani T; Remuzzi G
    Kidney Int; 1999 Feb; 55(2):674-85. PubMed ID: 9987092
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of early cyclosporine levels on kidney allograft rejection.
    Johnson EM; Canafax DM; Gillingham KJ; Humar A; Pandian K; Kerr SR; Najarian JS; Matas AJ
    Clin Transplant; 1997 Dec; 11(6):552-7. PubMed ID: 9408683
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of multidrug resistance P-glycoprotein in kidney allografts from cyclosporine A-treated patients.
    Koziolek MJ; Riess R; Geiger H; Thévenod F; Hauser IA
    Kidney Int; 2001 Jul; 60(1):156-66. PubMed ID: 11422747
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preservation of renal function during maintenance therapy with cyclosporine.
    Serón D; Moreso F
    Transplant Proc; 2004 Mar; 36(2 Suppl):257S-260S. PubMed ID: 15041349
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacodynamic monitoring of cyclosporin A reveals risk of opportunistic infections and malignancies in renal transplant recipients 65 years and older.
    Sommerer C; Schnitzler P; Meuer S; Zeier M; Giese T
    Ther Drug Monit; 2011 Dec; 33(6):694-8. PubMed ID: 22105585
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.